ArticleSeminars in nephrology2012
High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline.
Article in Seminars in nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- The effects of ursodeoxycholic acid on albuminuria in people with type 1 diabetes and diabetic kidney disease: a proof-of-concept study.Frontiers in endocrinology · 2026Trial
- Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes.PloS one · 2018Trial
- Role of the SLIT-ROBO signaling pathway in renal pathophysiology and various renal diseases.Frontiers in physiology · 2023Review
- Establishment and validation of the cut-off values of estimated glomerular filtration rate and urinary albumin-to-creatinine ratio for diabetic kidney disease: A multi-center, prospective cohort study.Frontiers in endocrinology · 2022Observational
- Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus.Physiological reports · 2019Article
- Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.Diabetes care · 2019Article
- The role of Slit-Robo signaling in the regulation of tissue barriers.Tissue barriers · 2017Review
- Association of prediabetes-associated single nucleotide polymorphisms with microalbuminuria.PloS one · 2017Article
- Beneficial effects of previous exercise training on renal changes in streptozotocin-induced diabetic female rats.Experimental biology and medicine (Maywood, N.J.) · 2016Article
- Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes.Diabetes care · 2015Review
- Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy.Journal of diabetes research · 2015Article
- Leptin monotherapy rescues spermatogenesis in male Akita type 1 diabetic mice.Endocrinology · 2014Article
- Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.Clinical and experimental nephrology · 2014Review
- Risk for end-stage renal disease over 25 years in the population-based WESDR cohort.Diabetes care · 2014Article
- The changing face of young-onset diabetes: type 1 optimism mellowed by type 2 concerns.Diabetes care · 2013Article
- Diabetic nephropathy: is ESRD its only heritable phenotype?Journal of the American Society of Nephrology : JASN · 2013Article
- Temporal profile of diabetic nephropathy pathologic changes.Current diabetes reports · 2013Review
- Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study.Current diabetes reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Care of patients with type 1 diabetes (T1D) has changed during the past 30 years. Tools to control hyperglycemia have improved and it was shown that improvement in glycemic control diminished the risk of late diabetic complications, including nephropathy. Moreover, in patients with impaired renal function, aggressive treatment of hypertension and renoprotective blockade of the renin-angiotensin system were shown to postpone end-stage renal disease (ESRD), albeit for a short while. Despite these achievements, the incidence of ESRD caused by T1D in the US population has not decreased but rather has increased over the past 20 years, although it now occurs at slightly older ages. This state of affairs is a call to action. This should begin with adopting a new model of diabetic nephropathy in human beings. In that model, instead of microalbuminuria or proteinuria, the focus should be on diagnosis and treatment of progressive renal function decline that leads to ESRD. Such a model has received significant support in clinical and epidemiologic studies. Investigation of mechanisms of such progressive renal function decline should help in the identification of new therapeutic targets and the development of new interventions. To evaluate these interventions, accurate diagnostic algorithms are needed so T1D patients will be stratified according to time to onset to ESRD. Consistent with concepts of personalized medicine, the new interventions should be tailored to and evaluated in patients predicted to have rapid, moderate, or even slow progression to ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.